Detailed information for compound 1776152
Basic information
Technical information
- Name: Unnamed compound
- MW: 488.639 | Formula: C26H36N2O5S
-
H donors: 2
H acceptors: 4
LogP: 1.69
Rotable bonds: 10
Rule of 5 violations (Lipinski): 1 - SMILES: CCCC[C@@]1(CC)N[C@H](c2ccccc2)c2c(S(=O)(=O)C1)cc(c(c2)OC)CN(CC(=O)O)C
- InChi: 1S/C26H36N2O5S/c1-5-7-13-26(6-2)18-34(31,32)23-14-20(16-28(3)17-24(29)30)22(33-4)15-21(23)25(27-26)19-11-9-8-10-12-19/h8-12,14-15,25,27H,5-7,13,16-18H2,1-4H3,(H,29,30)/t25-,26-/m1/s1
- InChiKey: YTNFDGWRKQEREI-CLJLJLNGSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | solute carrier family 10 (sodium/bile acid cotransporter), member 2 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Loa Loa (eye worm) | hypothetical protein | 0.0742 | 1 | 1 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Trypanosoma brucei | polo-like protein kinase | 0.0194 | 0.1483 | 0.5 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Schistosoma mansoni | serine/threonine protein kinase | 0.0194 | 0.1483 | 0.1483 |
| Onchocerca volvulus | 0.0742 | 1 | 1 | |
| Echinococcus granulosus | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Schistosoma mansoni | sodium-bile acid cotransporter related | 0.0301 | 0.3144 | 0.3144 |
| Giardia lamblia | Kinase, PLK | 0.0194 | 0.1483 | 0.5 |
| Echinococcus granulosus | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0194 | 0.1483 | 0.5 |
| Schistosoma mansoni | sodium-bile acid cotransporter | 0.0441 | 0.5324 | 0.5324 |
| Echinococcus multilocularis | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Trypanosoma cruzi | polo-like protein kinase, putative | 0.0194 | 0.1483 | 0.5 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Trypanosoma cruzi | polo-like protein kinase, putative | 0.0194 | 0.1483 | 0.5 |
| Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0194 | 0.1483 | 0.5 |
| Echinococcus granulosus | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Echinococcus multilocularis | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Echinococcus multilocularis | sodium bile acid cotransporter | 0.0742 | 1 | 1 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Trichomonas vaginalis | CAMK family protein kinase | 0.0194 | 0.1483 | 0.5 |
| Schistosoma mansoni | sodium-bile acid cotransporter related | 0.0742 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 41 nM | Inhibition of human ASBT expressed in HEK293 cells assessed as inhibition of [3H]-taurocholate uptake after 90 mins by scintillation counting analysis | ChEMBL. | 23678871 |
| IC50 (binding) | = 41 nM | BindingDB_Patents: Inhibition Assay. On the day of the uptake experiment, 10 mM HEPES was added to Hank's Balanced Salt Solution, and the pH was adjusted to 7.4 with TRIS (HBSSH). The assay buffer was prepared by adding 100 uM [3H]-taurocholate and 10 uM cold taurocholate to room temperature HBSSH. A separate washing buffer was prepared by adding 10 uM cold taurocholate to HBSSH (30 ml per assay plate) and placed on ice. Using 100% DMSO, 8 point, 3-fold dilution curves for each test compound was prepared starting at 200 uM. Similarly, an 8 point dose response curve was prepared of the control compound [(3R,5R)-3-butyl-3-ethyl-7,8-bis(methyloxy)-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1,1-dioxide (Brieaddy, L. E. WO9605188, 1996)] starting at 1.8 mM. Drug plates were created by adding 3 uL of each concentration to a v-bottom 96-well plate then diluted 60-fold with 177 uL of assay buffer. Plates were removed from the incubator and allowed to cool to ambient temperature. | ChEMBL. | No reference |
| IC50 (binding) | = 41 nM | BindingDB_Patents: Inhibition Assay. On the day of the uptake experiment, 10 mM HEPES was added to Hank's Balanced Salt Solution, and the pH was adjusted to 7.4 with TRIS (HBSSH). The assay buffer was prepared by adding 100 uM [3H]-taurocholate and 10 uM cold taurocholate to room temperature HBSSH. A separate washing buffer was prepared by adding 10 uM cold taurocholate to HBSSH (30 ml per assay plate) and placed on ice. Using 100% DMSO, 8 point, 3-fold dilution curves for each test compound was prepared starting at 200 uM. Similarly, an 8 point dose response curve was prepared of the control compound [(3R,5R)-3-butyl-3-ethyl-7,8-bis(methyloxy)-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1,1-dioxide (Brieaddy, L. E. WO9605188, 1996)] starting at 1.8 mM. Drug plates were created by adding 3 uL of each concentration to a v-bottom 96-well plate then diluted 60-fold with 177 uL of assay buffer. Plates were removed from the incubator and allowed to cool to ambient temperature. | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL2387398
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.